Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
127 studies found for:    "Gout"
Show Display Options
RSS Create an RSS feed from your search for:
Need help? See RSS Feeds
Choose a feed type:
Show studies that were first received in the last 14 daysShow studies that were first received in the last 14 days
Show studies added or modified in the last 14 daysShow studies that were added or modified in the last 14 days
Rank Status Study
1 Completed Initiation of Allopurinol at First Medical Contact for Acute Attacks of Gout
Conditions: Gout;   Gout Acute
Interventions: Drug: Allopurinol;   Drug: Placebo
2 Withdrawn Allopurinol in Acute Gout
Condition: Gout
Intervention: Drug: allopurinol
3 Completed
Has Results
Pegylated Recombinant Mammalian Uricase (PEG-uricase) as Treatment for Refractory Gout
Condition: Gout
Intervention: Biological: Pegloticase
4 Completed Assessment of Primary Care Providers' Knowledge and Beliefs Regarding Gout Management
Condition: Gout
5 Completed Long Term Study of Canakinumab (ACZ885) in Patients With Gout
Condition: Gout
Intervention: Drug: Canakinumab
6 Completed
Has Results
Evaluating Efficacy of Canakinumab (ACZ885) in Prevention of Acute Flares in Chronic Gout Patients Initiating Allopurinol Therapy
Condition: Gout
Interventions: Drug: Canakinumab 25 mg;   Drug: Canakinumab 50 mg;   Drug: Canakinumab 100 mg;   Drug: Canakinumab 200 mg;   Drug: Canakinumab 300 mg;   Drug: Canakinumab repeated every 4 week (q4wk);   Drug: Colchicine;   Drug: Allopurinol;   Drug: Placebo Matching Canakinumab;   Drug: Placebo Matching Colchicine
7 Completed Review of Safety Using Rilonacept in Preventing Gout Exacerbations (RE-SURGE)
Condition: Gout
Interventions: Biological: Rilonacept;   Other: Placebo
8 Completed
Has Results
Open-Label Extension Study for Patients Who Completed a Phase 3 Double-blind Study of PEG-uricase for Symptomatic Gout
Condition: Gout
Intervention: Biological: pegloticase
9 Completed PREventative Study Against URate-Lowering Drug-Induced Gout Exacerbations (PRE-SURGE 2)
Condition: Gout
Interventions: Drug: placebo;   Drug: rilonacept
10 Completed
Has Results
Does Allopurinol Prolong a Treated, Acute Gout Flare?
Condition: Gout
Interventions: Drug: allopurinol;   Drug: Placebo (sugar pill)
11 Completed Safety and Efficacy of Oral Febuxostat in Subjects With Gout
Condition: Gout
Interventions: Drug: Febuxostat;   Drug: Allopurinol
12 Active, not recruiting Lesinurad and Febuxostat Combination Extension Study in Gout
Condition: Gout
Intervention: Drug: lesinurad
13 Active, not recruiting Efficacy, Safety And Tolerability Of PF-06743649 In Gout Subjects.
Condition: Gout
Interventions: Drug: PF-06743649;   Other: Placebo
14 Completed Lesinurad Monotherapy in Gout Subjects Intolerant to Xanthine Oxidase Inhibitors
Condition: Gout
Interventions: Drug: lesinurad;   Drug: Placebo
15 Completed Italian Observational Study Assessing the Impact of Gout on Patients Disability and Quality of Life
Condition: Gout
16 Unknown  Study of Levotofisopam 50 mg Three Times a Day (TID) Administered for 7 Days on Hyperuricemia and Gout
Conditions: Hyperuricemia;   Gout
Intervention: Drug: levotofisopam
17 Completed A Study of Persons With Gout Who Do Not Respond to or Are Allergic to Conventional Therapy
Condition: Gout
Intervention: Drug: Puricase
18 Completed Study to Evaluate the Urate-Lowering Activity and Safety of Oral BCX4208 Administered in Subjects With Gout
Condition: Gout
Interventions: Drug: placebo;   Drug: BCX4208
19 Completed Open Label Safety/Efficacy Study of Arhalofenate in Combination With Febuxostat for Hyperuricemia in Gout Patients
Conditions: Hyperuricemia;   Gout
Interventions: Drug: Arhalofenate;   Drug: Febuxostat
20 Completed A Randomized, Double-Blind, Dose-Response Study of the Safety and Uric Acid Effects of Oral Ulodesine Added to Allopurinol in Subjects With Gout and Concomitant Moderate Renal Insufficiency
Conditions: Gout;   Hyperuricemia;   Arthritis;   Joint Disease;   Renal Insufficiency
Interventions: Drug: Placebo;   Drug: Ulodesine (BCX4208) 5 mg;   Drug: Ulodesine (BCX4208) 10 mg

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years